Independent guideFacts verified

Psychedelic therapy: what is available, what is regulated, and what is still in trials

The short answer: psychedelic-assisted therapy pairs a psychoactive medicine with structured clinical support. In the US today, what you can actually access depends on which of three doors a treatment sits behind.

  • Available by prescription: Ketamine and Esketamine (Spravato).
  • State-regulated programs: Psilocybin.
  • Investigational: MDMA and DMT.
  • IndependentNo affiliate links, sponsors or advertisers today.
  • Sources shownGovernment agencies and journals first. Every source is listed.
  • Not a clinicWe never sell or help obtain any substance.

Start here

Three doors. Knowing which one you are facing changes everything.

Headlines blur these together. A treatment you can be prescribed this month and one that exists only inside a research study are very different things. Every option in this guide is sorted into one of these categories.

  1. Door 1

    Available by prescription

    A licensed clinician can prescribe or administer it today, anywhere in the United States. One option is FDA-approved for depression. The other is an approved anesthetic used off-label.

  2. Door 2

    State-regulated programs

    Not a prescription medicine and still illegal under federal law, but offered to adults by licensed facilitators inside programs run by individual states.

  3. Door 3

    Investigational

    Not approved by the FDA and not legally sold as a treatment. The only legal access is taking part in a clinical trial.

Treatment explorer

Compare every option, side by side.

Filter by how you can access it or by what you are dealing with. Open any treatment for how it works in practice, the risks and the sources behind every line.

Checked against the cited sources on November 16, 2026

Filter by access

Filter by condition studied

Showing 5 of 5 treatments.

  • PrescriptionOff-label use

    Ketamine therapy

    Ketamine is an FDA-approved anesthetic that clinicians also prescribe off-label for depression, most often as an IV infusion in a clinic. The FDA has not approved ketamine for any psychiatric condition.

    Legal status
    Schedule III controlled substance. Legal with a prescription in every state. Psychiatric use is off-label, which is lawful but means the FDA has not reviewed it for that purpose.
    Cost
    Two October 2026 surveys of prices posted by U.S. clinics found a median of $450 to $475 per IV infusion, with posted prices from $250 to $950, and a median of roughly $2,700 to $2,900 for a six-infusion series.

    Evidence by condition

    • DepressionControlled trials

      Trials show rapid antidepressant effects in people who had not responded to other treatment. An expert consensus statement notes small study sizes and limited data on long-term benefit and safety.

    Access, sessions, risks and sources

    How it is accessed

    Prescribed by a licensed clinician. Given in clinics by IV infusion or injection. Some telehealth companies prescribe compounded tablets or lozenges for home use; federal rules allowing controlled substances to be prescribed by telemedicine without an in-person visit currently run through December 31, 2026, and the FDA has warned about the risks of compounded ketamine taken without on-site monitoring.

    What sessions look like

    In a clinic, an infusion typically takes about 40 to 60 minutes, followed by observation until the effects wear off. Clinics commonly sell a first course as a series of six infusions.

    Studied for

    • Treatment-resistant depression
    • Other mood and anxiety disorders (limited data)

    Known risks

    • Sedation and dissociation (feeling detached from your body or surroundings)
    • Increases in blood pressure
    • Slowed breathing (respiratory depression)
    • Urinary tract and bladder problems
    • Psychiatric side effects, and potential for abuse and misuse

    Who should be cautious

    • People with high blood pressure or heart or blood-vessel disease, because ketamine raises blood pressure
    • People with a history of substance misuse
    • People with a history of psychosis
    • Anyone considering compounded ketamine at home without a health care provider monitoring them
  • PrescriptionFDA-approved

    Esketamine (Spravato) nasal spray

    Spravato is a nasal spray form of esketamine, a close relative of ketamine. It is the only medicine in this guide that the FDA has approved for depression, and it can only be taken under supervision in a certified health care setting.

    Legal status
    Schedule III prescription drug. FDA-approved for adults with treatment-resistant depression, alone or with an oral antidepressant, and for depressive symptoms in adults with major depressive disorder and acute suicidal thoughts or behavior, together with an oral antidepressant.
    Cost
    Because it is FDA-approved, health plans including Medicare can cover it; what you pay depends on your plan. The drug alone cost pharmacies about $1,288 per 84 mg dose in October 2026 federal pricing data, before clinic fees.

    Evidence by condition

    • DepressionFDA-approved

      Approved for treatment-resistant depression and for depressive symptoms in major depressive disorder with acute suicidal thoughts or behavior. The label states it has not been shown to prevent suicide or reduce suicidal thoughts or behavior.

    Access, sessions, risks and sources

    How it is accessed

    Prescribed by a clinician and available only through a restricted safety program (the Spravato REMS). You take it yourself, under direct observation, at a certified health care setting. It is never dispensed for home use.

    What sessions look like

    You use the spray at the clinic and are monitored for at least two hours afterward, until a clinician confirms you are stable enough to leave. Treatment usually starts at twice a week for the first four weeks and becomes less frequent after that. You should not drive until the next day, after a restful sleep.

    Studied for

    • Treatment-resistant depression
    • Major depressive disorder with acute suicidal thoughts or behavior

    Known risks

    • Boxed warning: sedation, dissociation, slowed breathing, abuse and misuse, and suicidal thoughts and behaviors
    • Increases in blood pressure
    • Dizziness, nausea, vertigo, anxiety, and headache
    • Impaired attention, judgment, and reaction speed after dosing
    • May cause harm to an unborn baby

    Who should be cautious

    • Not for people with aneurysmal vascular disease, arteriovenous malformation, or a history of bleeding in the brain
    • People with high blood pressure or heart disease, because blood pressure is checked before and after each dose
    • People who are pregnant or planning a pregnancy
    • People with a history of substance misuse
    • Not approved for anyone under 18
  • State programOregon and Colorado

    Psilocybin services

    Psilocybin is the active compound in "magic mushrooms". It is not an approved medicine, but adults can legally take it with a licensed facilitator inside state-run programs in Oregon and Colorado. These programs are not medical treatment.

    Legal status
    Schedule I under federal law, so it is federally illegal and not FDA-approved. Oregon and Colorado license centers and facilitators to provide it to adults 21 and older. New Mexico passed a medical psilocybin law in 2025, and the state says that program is set to be implemented by December 31, 2026.
    Cost
    Paid out of pocket; states do not set prices and health insurance does not cover it. One booking marketplace lists about $750 for a group session and $1,500 to $3,500 for a private session in Oregon and Colorado, including preparation and integration (October 2026).

    Evidence by condition

    • DepressionPhase 3 trials

      Compass Pathways reports that two phase 3 trials of its synthetic psilocybin met their main goals in treatment-resistant depression, and it completed an application to the FDA on November 9, 2026. The FDA has not approved it.

    • Substance useControlled trials

      In a 2022 trial of 93 people with alcohol use disorder, psilocybin with psychotherapy led to fewer heavy drinking days over 32 weeks than placebo with psychotherapy. Most participants could tell which they had received.

    • End-of-life distressEarly research

      A 2020 analysis of four small studies, mostly in people with life-threatening cancer, found improvements in anxiety and depression. The authors noted the results may have been biased.

    Access, sessions, risks and sources

    How it is accessed

    In Oregon you contact a licensed service center directly. You must be 21 or older; no prescription, referral, or Oregon residency is required. In Colorado, sessions take place at state-licensed healing centers with licensed facilitators. Outside these programs, legal access is through clinical trials.

    What sessions look like

    Oregon requires a preparation session with a licensed facilitator before the session in which you take psilocybin, which happens at the licensed center. Preparation includes a safety and support plan and a transportation plan. A follow-up integration session is commonly offered.

    Studied for

    • Treatment-resistant depression
    • Major depressive disorder
    • Alcohol use disorder
    • Anxiety and distress in serious illness

    Known risks

    • Raised blood pressure and heart rate
    • Headache, nausea, dizziness, and fatigue
    • Anxiety and paranoia during the experience
    • Persistent psychosis in vulnerable people
    • Products obtained outside licensed programs can be contaminated or misidentified

    Who should be cautious

    • Not safe for people with psychotic conditions such as schizophrenia or schizoaffective disorder
    • Not safe for people with severe forms of bipolar disorder or borderline personality disorder
    • People taking antidepressants or other psychiatric medicines, because interactions are still being studied
    • People with heart conditions or high blood pressure
  • InvestigationalNot approved

    MDMA-assisted therapy

    MDMA combined with talk therapy has been tested in late-stage trials for PTSD. The FDA declined to approve it in August 2024 and asked for more research. It is not legally available as a treatment.

    Legal status
    Schedule I under federal law. The FDA has not approved MDMA for any medical condition. In August 2026 the nonprofit that began the trials said the application had reportedly been resubmitted to the FDA by Resilient Pharmaceuticals (formerly Lykos Therapeutics). No decision has been announced.
    Cost
    There is no legal treatment to buy. The only legal access is through a clinical trial.

    Evidence by condition

    • PTSDPhase 3 trials

      Two phase 3 trials have been published. In its August 2024 response, the FDA asked for more research on how long the benefit lasts, on safety, and on reducing bias, since most participants could tell whether they had received MDMA.

    Access, sessions, risks and sources

    How it is accessed

    Only by taking part in a clinical trial. Anything sold as MDMA therapy outside a trial is unregulated and illegal under federal law.

    What sessions look like

    In the phase 3 trials, participants took MDMA in three day-long sessions spaced about a month apart, with therapists present, plus therapy sessions for preparation beforehand and integration afterward.

    Studied for

    • Post-traumatic stress disorder (PTSD)

    Known risks

    • Raised blood pressure
    • Jaw clenching, nausea, and vomiting
    • A dangerous rise in body temperature in some settings
    • Heart or liver problems with long-term use
    • MDMA obtained outside research may contain other dangerous substances

    Who should be cautious

    • People with heart conditions or high blood pressure
    • People taking antidepressants such as SSRIs, which may increase the risk of harmful effects
    • People with a history of psychosis or bipolar disorder, who are generally excluded from psychedelic research as a precaution
  • InvestigationalClinical trials only

    DMT and 5-MeO-DMT

    DMT and the related compound 5-MeO-DMT are fast-acting psychedelics whose effects last minutes rather than hours. Drug companies are testing them for depression. Neither is approved or legally available as a treatment.

    Legal status
    Both are Schedule I under federal law and not FDA-approved. Research versions, including an intranasal 5-MeO-DMT (mebufotenin) and an inhaled 5-MeO-DMT (GH001), are in clinical trials.
    Cost
    There is no legal treatment to buy. The only legal access is through a clinical trial.

    Evidence by condition

    • DepressionControlled trials

      In a 2026 phase 2b trial of 193 adults with treatment-resistant depression, a single 12 mg dose of intranasal 5-MeO-DMT reduced depression scores more than a very low comparison dose at day 29. Larger phase 3 trials have not yet reported.

    Access, sessions, risks and sources

    How it is accessed

    Only by taking part in a clinical trial. Ayahuasca, a plant brew that contains DMT, is not an approved treatment either.

    What sessions look like

    Sessions are short. In studies, the effects of intravenous DMT resolved within 20 to 30 minutes, and most participants given intranasal 5-MeO-DMT were judged ready to go home within two hours.

    Studied for

    • Treatment-resistant depression
    • Postpartum depression (early trial)

    Known risks

    • Nausea
    • Short-lived increases in heart rate and blood pressure
    • An intense, sometimes frightening experience with rapid onset
    • Side effects were reported by most trial participants, and nearly all were mild or moderate

    Who should be cautious

    • People with heart conditions or high blood pressure
    • People with a history of psychosis or bipolar disorder, who are generally excluded from psychedelic research as a precaution
    • Anyone considering use outside a clinical trial, where dose and contents are unknown

At a glance

The whole landscape in one table.

Access category, regulatory status and estimated cost for each treatment in this guide. Scroll sideways on small screens.
TreatmentAccessLegal statusHow accessedCost
KetaminePrescriptionOff-label useSchedule III controlled substance. Legal with a prescription in every state. Psychiatric use is off-label, which is lawful but means the FDA has not reviewed it for that purpose.Prescribed by a licensed clinician. Given in clinics by IV infusion or injection. Some telehealth companies prescribe compounded tablets or lozenges for home use; federal rules allowing controlled substances to be prescribed by telemedicine without an in-person visit currently run through December 31, 2026, and the FDA has warned about the risks of compounded ketamine taken without on-site monitoring.Two October 2026 surveys of prices posted by U.S. clinics found a median of $450 to $475 per IV infusion, with posted prices from $250 to $950, and a median of roughly $2,700 to $2,900 for a six-infusion series.
Esketamine (Spravato)PrescriptionFDA-approvedSchedule III prescription drug. FDA-approved for adults with treatment-resistant depression, alone or with an oral antidepressant, and for depressive symptoms in adults with major depressive disorder and acute suicidal thoughts or behavior, together with an oral antidepressant.Prescribed by a clinician and available only through a restricted safety program (the Spravato REMS). You take it yourself, under direct observation, at a certified health care setting. It is never dispensed for home use.Because it is FDA-approved, health plans including Medicare can cover it; what you pay depends on your plan. The drug alone cost pharmacies about $1,288 per 84 mg dose in October 2026 federal pricing data, before clinic fees.
PsilocybinState programOregon and ColoradoSchedule I under federal law, so it is federally illegal and not FDA-approved. Oregon and Colorado license centers and facilitators to provide it to adults 21 and older. New Mexico passed a medical psilocybin law in 2025, and the state says that program is set to be implemented by December 31, 2026.In Oregon you contact a licensed service center directly. You must be 21 or older; no prescription, referral, or Oregon residency is required. In Colorado, sessions take place at state-licensed healing centers with licensed facilitators. Outside these programs, legal access is through clinical trials.Paid out of pocket; states do not set prices and health insurance does not cover it. One booking marketplace lists about $750 for a group session and $1,500 to $3,500 for a private session in Oregon and Colorado, including preparation and integration (October 2026).
MDMAInvestigationalNot approvedSchedule I under federal law. The FDA has not approved MDMA for any medical condition. In August 2026 the nonprofit that began the trials said the application had reportedly been resubmitted to the FDA by Resilient Pharmaceuticals (formerly Lykos Therapeutics). No decision has been announced.Only by taking part in a clinical trial. Anything sold as MDMA therapy outside a trial is unregulated and illegal under federal law.There is no legal treatment to buy. The only legal access is through a clinical trial.
DMTInvestigationalClinical trials onlyBoth are Schedule I under federal law and not FDA-approved. Research versions, including an intranasal 5-MeO-DMT (mebufotenin) and an inhaled 5-MeO-DMT (GH001), are in clinical trials.Only by taking part in a clinical trial. Ayahuasca, a plant brew that contains DMT, is not an approved treatment either.There is no legal treatment to buy. The only legal access is through a clinical trial.

By condition

What each treatment has been studied for, and how strong that evidence is.

"Studied for" is not the same as "proven for". These are the evidence levels we use:

FDA-approved
FDA-approved. The FDA reviewed the trial evidence and approved the drug for this condition.
Phase 3 trials
Phase 3 trials. Large late-stage trials have reported results, but the FDA has not approved the drug for this use.
Controlled trials
Controlled trials. Randomized trials have been published, usually small or short. Not approved for this use.
Early research
Early research. A few small studies only. Too little to draw conclusions.
Evidence level by treatment and condition. A dash means not studied for that condition in our sources.
ConditionKetamineEsketamine (Spravato)PsilocybinMDMADMT
DepressionControlled trialsFDA-approvedPhase 3 trials–Controlled trials
PTSD–––Phase 3 trials–
Anxiety–––––
Substance use––Controlled trials––
End-of-life distress––Early research––

On the horizon

Emerging treatments: real research, not real options yet.

You will see these in the news. Here is where each one actually stands, so a hopeful headline does not become a risky decision.

Safety, plainly

These are powerful medicines. They are not right for everyone.

Psychedelic therapy is not a shortcut, and a good clinician will screen you carefully before recommending any of it. Below is who the sources say should be especially cautious with each treatment. Use it to prepare honest questions, not to rule yourself in or out.

Ketamine: who should be cautious
  • People with high blood pressure or heart or blood-vessel disease, because ketamine raises blood pressure
  • People with a history of substance misuse
  • People with a history of psychosis
  • Anyone considering compounded ketamine at home without a health care provider monitoring them
Esketamine (Spravato): who should be cautious
  • Not for people with aneurysmal vascular disease, arteriovenous malformation, or a history of bleeding in the brain
  • People with high blood pressure or heart disease, because blood pressure is checked before and after each dose
  • People who are pregnant or planning a pregnancy
  • People with a history of substance misuse
  • Not approved for anyone under 18
Psilocybin: who should be cautious
  • Not safe for people with psychotic conditions such as schizophrenia or schizoaffective disorder
  • Not safe for people with severe forms of bipolar disorder or borderline personality disorder
  • People taking antidepressants or other psychiatric medicines, because interactions are still being studied
  • People with heart conditions or high blood pressure
MDMA: who should be cautious
  • People with heart conditions or high blood pressure
  • People taking antidepressants such as SSRIs, which may increase the risk of harmful effects
  • People with a history of psychosis or bipolar disorder, who are generally excluded from psychedelic research as a precaution
DMT: who should be cautious
  • People with heart conditions or high blood pressure
  • People with a history of psychosis or bipolar disorder, who are generally excluded from psychedelic research as a precaution
  • Anyone considering use outside a clinical trial, where dose and contents are unknown

Never combine, stop or change medications on your own. Bring your full medication list and history to a licensed clinician.

What we are building next

The next questions are about who, where and how much.

These guides are not published yet. We will not rush them. When each one meets our review methodology, we will tell you.

  1. Provider comparisonsUpcoming

    Clinics and programs, evaluated against our published criteria.

  2. Pricing guidesUpcoming

    What care really costs, including what insurance may cover.

  3. Independent reviewsUpcoming

    Plain verdicts, with no payment influencing the outcome.

  4. Treatment finderUpcoming

    A short, private tool to narrow options to the ones that fit.

Get one email when it is ready.

Pick what you care about. We will write once per launch you choose. No newsletter, no marketing list, and we will remove you whenever you ask. See our privacy policy.

What should we tell you about? (optional)

One email per launch you choose. Nothing else.

Questions people ask

Frequently asked questions

Have a question we have not answered? Write to the editorial team.

Is psychedelic therapy legal in the United States?

It depends on the substance. Esketamine (Spravato) is FDA-approved and ketamine can be prescribed off-label, so both are legal nationwide with a prescription. Psilocybin is federally illegal but offered to adults through state-licensed programs in Oregon and Colorado. MDMA, DMT, LSD, and ibogaine are not approved and are legally available only in clinical trials.

Which psychedelic treatments are FDA-approved?

Only one: esketamine nasal spray (Spravato), for treatment-resistant depression and for depressive symptoms in adults with major depressive disorder and acute suicidal thoughts or behavior. Ketamine is FDA-approved as an anesthetic, not for any psychiatric condition. Psilocybin, MDMA, DMT, and LSD are not FDA-approved.

What is the difference between ketamine and esketamine (Spravato)?

Esketamine is a close chemical relative of ketamine made as a nasal spray. It is FDA-approved for depression, must be taken under supervision in a certified health care setting, and health plans can cover it. Ketamine for depression is an off-label use, most often given by IV infusion, and clinics typically post self-pay prices.

Do I need a prescription for psilocybin in Oregon or Colorado?

No. Oregon states that a prescription or medical referral is not required, and that you do not need to live in Oregon. You must be 21 or older and complete a preparation session with a licensed facilitator first. These are state-regulated services, not medical treatment, and psilocybin remains illegal under federal law.

How much does psychedelic therapy cost?

Surveys of posted clinic prices in October 2026 put the median IV ketamine infusion at $450 to $475. One marketplace lists legal psilocybin sessions in Oregon and Colorado at about $750 for a group session and $1,500 to $3,500 for a private one. Spravato costs depend on your health plan. MDMA and DMT are not for sale as treatments.

Is MDMA therapy available for PTSD?

Not outside clinical trials. The FDA declined to approve MDMA-assisted therapy in August 2024 and asked for more research. A resubmitted application was reported in August 2026, and no decision has been announced.

Who should not use psychedelic therapy?

The answer differs by substance, so check the cautions listed for each treatment above. In general, people with a personal history of psychosis or bipolar disorder are excluded from modern psychedelic research as a precaution, and several of these substances raise blood pressure, which matters for people with heart conditions. Only a clinician who knows your history can tell you whether a treatment is appropriate for you.

Does Psychedelic Therapy Index provide medical advice or recommend providers?

No. This site is general education, not medical advice, and it does not currently review, rank, or link to any provider. Speak with a licensed clinician before making a decision about treatment.

Sources

Every source cited on this page

Verified on November 16, 2026. Found something out of date? Report a correction.

  1. 1.Warning on compounded ketamine for psychiatric disorders (October 2023) — U.S. Food and Drug Administration (opens in a new tab)
  2. 2.Drug scheduling — U.S. Drug Enforcement Administration (opens in a new tab)
  3. 3.A consensus statement on the use of ketamine in the treatment of mood disorders (2017) — JAMA Psychiatry (opens in a new tab)
  4. 4.Telemedicine prescribing flexibilities extended through 2026 — U.S. Department of Health and Human Services (opens in a new tab)
  5. 5.Ketamine therapy prices published by U.S. clinics (October 2026) — KetamineHQ price survey (opens in a new tab)
  6. 6.Ketamine and Spravato cost analysis (fourth quarter 2026) — Signal Hill Strategies price survey (opens in a new tab)
  7. 7.Spravato (esketamine) prescribing information — DailyMed, National Library of Medicine (opens in a new tab)
  8. 8.Spravato REMS program requirements — Spravato REMS (opens in a new tab)
  9. 9.Psilocybin for mental health and addiction: what you need to know — National Center for Complementary and Integrative Health (opens in a new tab)
  10. 10.How to access psilocybin services — Oregon Health Authority (opens in a new tab)
  11. 11.Natural Medicine Division: licensed healing centers — Colorado Department of Revenue (opens in a new tab)
  12. 12.Colorado Natural Medicine Program: facilitator licensing — Colorado Department of Regulatory Agencies (opens in a new tab)
  13. 13.Medical Psilocybin Program — New Mexico Department of Health (opens in a new tab)
  14. 14.COMP360 psilocybin application to the FDA completed (November 9, 2026) — Compass Pathways company announcement (opens in a new tab)
  15. 15.Legal psilocybin session prices in Oregon and Colorado (October 2026) — Althea, a psilocybin booking marketplace (opens in a new tab)
  16. 16.MDMA (Ecstasy/Molly) — National Institute on Drug Abuse (opens in a new tab)
  17. 17.Statement on the reported resubmission of the MDMA-assisted therapy application (August 10, 2026) — Multidisciplinary Association for Psychedelic Studies (opens in a new tab)
  18. 18.MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial (2023) — Nature Medicine (opens in a new tab)
  19. 19.Schedule I controlled substances, 21 CFR 1308.11 — Code of Federal Regulations (opens in a new tab)
  20. 20.Psychedelic and dissociative drugs — National Institute on Drug Abuse (opens in a new tab)
  21. 21.Intranasal mebufotenin (5-MeO-DMT) for treatment-resistant depression: phase 2b randomized trial (2026) — JAMA (opens in a new tab)
  22. 22.N,N-DMT and 5-MeO-DMT: systematic review of clinical and safety evidence (2026) — Progress in Neuro-Psychopharmacology and Biological Psychiatry (opens in a new tab)
  23. 23.DT120 phase 3 announcements — Definium Therapeutics company announcements (opens in a new tab)
  24. 24.FDA seeks public input to support ibogaine research (October 2026) — U.S. Food and Drug Administration (opens in a new tab)
  25. 25.ARPA-H awards to advance ibogaine development for PTSD (November 12, 2026) — U.S. Department of Health and Human Services (opens in a new tab)

This guide is for education only and is not medical advice. It does not create a clinician-patient relationship. Read our terms and medical review policy.